ClinicalTrials.gg
RecruitingNCT064123157T FACESUpdated Oct 2, 2026

7T Amygdala and Citalopram Study

An interventional study of Citalopram and Placebo in Emotional Processing, Cognition and Mood Disorders, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionDepressive DisorderRegistry: Mood DisordersReclassifiedWhy we changed it
Registry
Mood Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depressive Disorder
Why
  1. The study's listed conditions name Depressive Disorder, a narrower term within Mood Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Oxford · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Depressive Disorder by University of Oxford — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder · University of Oxford.

Planned enrollment
5th of 10
54 · median 54
Started
2025
the only one that year
No phase
8 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Depressive Disorder by University of Oxford, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 8 with no phase, and was the 10th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

1 of the 10 studies in Depressive Disorder by University of Oxford is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder by University of Oxford, or all of them as a file.
02

Study summary

The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information.

Healthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces. Since the scan uses high field strength, the investigators will be able to see effects of citalopram on different subfields within the amygdala which will help to understand how citalopram might be working.

Read the detailed description

Antidepressants typically decrease amygdala response to negative stimuli while enhancing response to positive stimuli, but it is unclear at a mechanistic level how increasing serotonin would have this opposing effect. One hypothesis is that although positive and negative cues activate the same area at a global level, more detailed characterisation may reveal key differences in processing in terms of localisation or response function. Until now, due to methodological restriction, the amygdala has been mostly studied as a single structure. It is however known that it consists of a number of subfields, which are likely to play distinct roles in emotional processing. In this study the investigators will make use of 7T fMRI scanning to study the effects of a single dose (20 mg) of citalopram (selective serotonin reuptake inhibitor, SSRI) on these subfields during emotional face processing, allowing greater precision to identify underlying neural mechanisms underpinning psychological effects.

03

Conditions studied

  • Emotional Processing
  • Cognition
  • Mood Disorders
  • Depressive Disorder
  • Depression

Browse trials for

Keywords

  • Antidepressants
  • Experimental medicine
  • Psychopharmacology
  • Emotional Processing
  • fMRI
  • High field strength fMRI
  • 7 Tesla MRI
04

In context

Depressive Disorder Reclassified

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

This study's planned enrollment of 54 is below the median of 87 across 691 interventional studies indexed under Depressive Disorder.

Browse Depressive Disorder studies →

Lead sponsor

University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.

Compared within Depressive Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mood Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the research
  • Sufficiently fluent English to understand and complete the task

Exclusion criteria

Exclusion Criteria:

  • Participants with ferromagnetic objects in their bodies (e.g. metal implants, vessel clips, shrapnel injuries) or with implanted devices which may be damaged by the magnet (e.g. heart pacemakers)
  • Any other MRI following MRI safety screening
  • History or current significant psychiatric illness (like major depressive disorder)
  • Current or past diagnosis of any significant personality disorder (e.g. borderline personality disorder) according to self-report
  • Diagnosis of attention deficit hyperactive disorder or autistic spectrum disorder that impairs daily functioning, requires pharmacotherapy or in the opinion of the study medic would affect the scientific integrity of the study
  • Currently or within last 3 months taking psychoactive medications (requires further discussion with researcher)
  • Current or within the last 3 months use of medication that might interact with the effects of citalopram or affect the scientific integrity of the study
  • Known contraindication to citalopram including: past allergic reaction to citalopram or any other medicines, diagnosis of a cardiovascular condition, glaucoma, type 1 or type 2 diabetes, diagnosis of epilepsy, previous diagnosis of angle-closure glaucoma, or current use of any other medication whose use interacts with citalopram (according to British National Formulary (BNF) guidance) e.g. associated with prolonged -interval
  • Any other current or past medical conditions which in the opinion of the study medic may interfere with the safety of the participant or the scientific integrity of the study including epilepsy/seizures, brain injury, hepatic or renal disease, diabetes, severe gastro-intestinal problems, Central Nervous System (CNS) tumours, neurological conditions
  • abnormal values for urine drug screen, pulse, and blood pressure measurement (in accordance with Best Practice Guidance 13: 'Non-invasive measurement of blood pressure'). A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
  • Current alcohol or substance misuse disorder
  • under 17 and over 35
  • Pregnant or planning a pregnancy, or breast feeding
  • Previously taken part in a study that used similar computer tasks (MRI faces task, emotional test battery) as those in the present study
  • Participation in a study that involves the use of a psychoactive medication or brain stimulation within the last three months
  • Use of recreational drugs (e.g. cannabis, cocaine, amphetamines) within last three months
  • Smoking > 5 cigarettes per day, or vape a comparable amount (> 0.5ml / a quarter of a 2ml vape);
  • Typically drinks > 6 caffeinated drinks per day (e.g. tea, coffee, coca cola, Red Bull)
  • Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Citalopram

    Drug: Citalopram

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.

  • DrugPlacebo

    Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once

07

What researchers measure

Primary outcomes

  1. Neural measures: fMRI BOLD univariate analysis

    Blood-oxygen-level-dependent (BOLD) fMRI (region of interest (ROI) analysis amygdala) during the performance of an emotional faces task. Differential amygdala response to fearful and happy faces. Univariate analysis

    Time frame: 3 hours after dosing for approximately 1 hour

  2. Neural measures: fMRI BOLD multivariate analysis

    Blood-oxygen-level-dependent (BOLD) fMRI (region of interest (ROI) analysis amygdala) during the performance of an emotional faces task. Amygdala response to fearful and happy faces. Multivariate pattern analysis.

    Time frame: 3 hours after dosing for approximately 1 hour

Secondary outcomes

  1. Behavioural measures: Accuracy during gender discrimination task

    Accuracy (% correct) of gender identification will be measured to ensure participant engagement throughout the task.

    Time frame: 3 hours after dosing for approximately 1hour

  2. Behavioural measures: Reaction times during gender discrimination task

    Reaction times (ms) of gender identification will be measured to ensure participant engagement throughout the task.

    Time frame: 3 hours after dosing for approximately 1hour

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Apr 2027, 26 months after the start.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 26 months is below that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
May 14, 2024
StartActual
Feb 13, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06412315
Responsible party
Catherine Harmer (Professor of Cognitive Neuroscience, University of Oxford) — Principal investigator
First posted
May 14, 2024
Start date
Feb 13, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Marieke AG Martens, DPhil
Contact
marieke.martens@psych.ox.ac.uk
+441865 618338
Catherine J Harmer, DPhil
Contact
catherine.harmer@psych.ox.ac.uk
+441865 618326

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Citalopram

Start the discussion